|
1
|
Bonnot PE and Passot G: RAS mutation: Site
of disease and recurrence pattern in colorectal cancer. Chin Clin
Oncol. 8:55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xi Y and Xu P: Global colorectal cancer
burden in 2020 and projections to 2040. Transl Oncol.
14:1011742021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jordan Cancer Registry, . Cancer Incidence
in Jordan. Minist Heal Jordan. 11:15–17. 2018.
|
|
5
|
Sharkas GF, Arqoub KH, Khader YS, Tarawneh
MR, Nimri OF, Al-Zaghal MJ and Subih HS: Colorectal cancer in
Jordan: Survival rate and its related factors. J Oncol.
2017:31807622017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saoudi González N, Salvà F, Ros J,
Baraibar I, Rodríguez-Castells M, García A, Alcaráz A, Vega S,
Bueno S, Tabernero J and Elez E: Unravelling the complexity of
colorectal cancer: Heterogeneity, clonal evolution, and clinical
implications. Cancers (Basel). 15:40202023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dienstmann R, Connor K and Byrne AT:
Precision therapy in RAS mutant colorectal cancer.
Gastroenterology. 158:806–811. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gong J, Cho M and Fakih M: RAS and BRAF in
metastatic colorectal cancer management. J Gastrointest Oncol.
7:6872016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsuchida N, Murugan AK and Grieco M:
Kirsten ras oncogene: Significance of its discovery in human cancer
research. Oncotarget. 7:467172016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lakatos G, Köhne CH and Bodoky G: Current
therapy of advanced colorectal cancer according to RAS/RAF
mutational status. Cancer Metastasis Rev. 39:1143–1157. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takane K, Akagi K, Fukuyo M, Yagi K,
Takayama T and Kaneda A: DNA methylation epigenotype and clinical
features of NRAS-mutation(+) colorectal cancer. Cancer Med.
6:1023–1035. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cercek A, Braghiroli MI, Chou JF, Hechtman
JF, Kemeny N, Saltz L, Capanu M and Yaeger R: Clinical features and
outcomes of patients with colorectal cancers harboring NRAS
mutations. Clin Cancer Res. 23:4753–4760. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Loree JM, Yu C, Tschautscher M,
Overman MJ, Broaddus R and Grothey A: Distinct impacts of KRAS,
NRAS and BRAF mutations on survival of patients with metastatic
colorectal cancer. J Clin Oncol. 36:3513. 2018. View Article : Google Scholar
|
|
14
|
Vigil D, Cherfils J, Rossman KL and Der
CJ: Ras superfamily GEFs and GAPs: Validated and tractable targets
for cancer therapy? Nat Rev Cancer. 10:842–857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan AQ, Kuttikrishnan S, Siveen KS,
Prabhu KS, Shanmugakonar M, Al-Naemi HA, Haris M, Dermime S and
Uddin S: RAS-mediated oncogenic signaling pathways in human
malignancies. Semin Cancer Biol. 54:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colussi D, Brandi G, Bazzoli F and
Ricciardiello L: Molecular pathways involved in colorectal cancer:
Implications for disease behavior and prevention. Int J Mol Sci.
14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Newhall K, Price T, Peeters M, Kim TW, Li
J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, et al:
Frequency of S492R mutations in the epidermal growth factor
receptor: Analysis of plasma dna from metastatic colorectal cancer
patients treated with panitumumab or cetuximab monotherapy. Ann
Oncol. 25:II1092014. View Article : Google Scholar
|
|
18
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng M, Zhong K, Jiang T, Liu Z, Kwan HY
and Su T: The current understanding on the impact of KRAS on
colorectal cancer. Biomed Pharmacother. 140:1117172021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richman SD, Seymour MT, Chambers P,
Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH and Quirke P:
KRAS and BRAF mutations in advanced colorectal cancer are
associated with poor prognosis but do not preclude benefit from
oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin
Oncol. 27:5931–5937. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nat.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li ZN, Zhao L, Yu LF and Wei MJ: BRAF and
KRAS mutations in metastatic colorectal cancer: Future perspectives
for personalized therapy. Gastroenterol Rep. 8:192–205. 2020.
View Article : Google Scholar
|
|
23
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kopetz S, Desai J, Chan E, Hecht JR,
O'Dwyer PJ, Lee RJ, Nolop KB and Saltz L: PLX4032 in metastatic
colorectal cancer patients with mutant BRAF tumors. J Clin Oncol.
28 (Suppl 15):S3534. 2010. View Article : Google Scholar
|
|
25
|
Avădănei ER, Căruntu ID, Nucă I, Balan RA,
Lozneanu L, Giusca SE, Pricope DL, Dascalu CG and Amalinei C: KRAS
mutation status in relation to clinicopathological characteristics
of romanian colorectal cancer patients. Curr Issues Mol Biol.
47:1202025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li WQ, Kawakami K, Ruszkiewicz A, Bennett
G, Moore J and Iacopetta B: BRAF mutations are associated with
distinctive clinical, pathological and molecular features of
colorectal cancer independently of microsatellite instability
status. Mol Cancer. 5:22006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koochak A, Rakhshani N, Karbalaie Niya MH,
Tameshkel FS, Sohrabi MR, Babaee MR, Rezvani H, Bahar B, Imanzade
F, Zamani F, et al: Mutation analysis of KRAS and BRAF genes in
metastatic colorectal cancer: A First large scale study from iran.
Asian Pacific J Cancer Prev. 17:603–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawazoe A, Shitara K, Fukuoka S, Kuboki Y,
Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, et al: A
retrospective observational study of clinicopathological features
of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with
metastatic colorectal cancer. BMC Cancer. 15:2582015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stintzing S, Tejpar S, Gibbs P, Thiebach L
and Lenz HJ: Understanding the role of primary tumour localisation
in colorectal cancer treatment and outcomes. Eur J Cancer.
84:69–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li C, Wang Q and Jiang KW: What is the
best surgical procedure of transverse colon cancer? An evidence map
and minireview. World J Gastrointest Oncol. 13:3912021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Siegel RL, Wagle NS, Cercek A, Smith RA
and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin.
73:233–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pirvu EE, Severin E, Niţă I and Toma
Ștefania A: The impact of RAS mutation on the treatment strategy of
colorectal cancer. Med Pharm Rep. 96:5–15. 2023.PubMed/NCBI
|
|
34
|
Dempke WC and Heinemann V: Ras mutational
status is a biomarker for resistance to EGFR inhibitors in
colorectal carcinoma. Anticancer Res. 30:4673–4677. 2010.PubMed/NCBI
|
|
35
|
Ibrahimi AKH, Al-Hussaini M, Laban DA,
Ammarin R, Wehbeh L and Al-Mousa A: Cetuximab plus XELOX show
efficacy against brain metastasis from colorectal cancer: A case
report. CNS Oncol. 12:CNS972023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rimbert J, Tachon G, Junca A, Villalva C,
Karayan-Tapon L and Tougeron D: Association between
clinicopathological characteristics and RAS mutation in colorectal
cancer. Mod Pathol. 31:517–526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sughayer WM and Sughayer MA: KRAS
mutations and subtyping in colorectal cancer in Jordanian patients.
Oncol Lett. 4:705–710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Afrǎsânie VA, Marinca MV, Alexa-Stratulat
T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L and Rusu C: KRAS,
NRAS, BRAF, HER2 and microsatellite instability in metastatic
colorectal cancer-practical implications for the clinician. Radiol
Oncol. 53:265–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Levi M, Prayogi G, Sastranagara F,
Sudianto E, Widjajahakim G, Gani W, Mahanadi A, Agnes J, Khairunisa
BH and Utomo AR: Clinicopathological associations of K-RAS and
N-RAS mutations in indonesian colorectal cancer cohort. J
Gastrointest Cancer. 49:124–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ye ZL, Qiu MZ, Tang T, Wang F, Zhou YX,
Lei MJ, Guan WL and He CY: Gene mutation profiling in Chinese
colorectal cancer patients and its association with
clinicopathological characteristics and prognosis. Cancer Med.
9:745–756. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu
T, Sun J, Jiang H, Zhu Y, Zheng Y, et al: Molecular spectrum of
KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer
patients: Analysis of 1,110 cases. Sci Rep. 5:186782015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang X, Ran W, Wu J, Li H, Liu H, Wang L,
Xiao Y, Wang X, Li Y and Xing X: Deficient mismatch repair and RAS
mutation in colorectal carcinoma patients: A retrospective study in
Eastern China. PeerJ. 6:e43412018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jauhri M, Bhatnagar A, Gupta S, Manasa BP,
Minhas S, Shokeen Y and Aggarwal S: Prevalence and coexistence of
KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian
colorectal cancer patients: Next-generation sequencing-based cohort
study. Tumor Biol. 39:10104283176922652017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Negru S, Papadopoulou E, Apessos A,
Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S,
Aravantinos G, Ziras N, et al: KRAS, NRAS and BRAF mutations in
Greek and Romanian patients with colorectal cancer: A cohort study.
BMJ Open. 4:e0046522014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour
I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan
MM, et al: Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53,
and APC somatic gene mutations in Arab patients with colorectal
cancer: Determination of frequency and distribution pattern. J
Gastrointest Oncol. 7:882–902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ouerhani S, Bougatef K, Soltani I,
Elgaaied ABA, Abbes S and Menif S: The prevalence and prognostic
significance of KRAS mutation in bladder cancer, chronic myeloid
leukemia and colorectal cancer. Mol Biol Rep. 40:4109–4114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol (Madr). 53:852–864. 2014. View Article : Google Scholar
|
|
50
|
Loupakis F, Ruzzo A, Cremolini C, Vincenzi
B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E,
et al: KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Karapetis CS, Jonker D, Daneshmand M,
Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore
MJ, Tebbutt NC, et al: PIK3CA, BRAF, and PTEN status and benefit
from cetuximab in the treatment of advanced colorectal
cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res.
20:744–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mounjid C, El Agouri H, Mahdi Y, Laraqui
A, Chtati E, Ech-charif S, Khmou M, Bakri Y, Souadka A and Souadka
BE: Assessment of KRAS and NRAS status in metastatic colorectal
cancer: Experience of the national institute of oncology in rabat
morocco. Ann Cancer Res Ther. 30:80–84. 2022. View Article : Google Scholar
|
|
53
|
Zanatto RM, Santos G, Oliveira JC,
Pracucho EM, Nunes AJF, Lopes-Filho GJ and Saad SS: Impact of kras
mutations in clinical features in colorectal cancer. Arq Bras Cir
Dig. 33:e15242020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Taïeb J, Emile JF, Malicot K, Zaanan A,
Tabernero J, Mini E, Rougier P, Van Laethem JL, Bridgewater JA,
Folprecht G, et al: Prognostic value of KRAS exon 2 gene mutations
in stage III colon cancer: Post hoc analyses of the PETACC8 trial.
J Clin Oncol. 32:3549. 2014. View Article : Google Scholar
|
|
55
|
Ounissi D, Weslati M, Boughriba R, Hazgui
M and Bouraoui S: Clinicopathological characteristics and
mutational profile of KRAS and NRAS inTunisian patients with
sporadic colorectal cancer. Turkish J Med Sci. 51:148–158.
2021.PubMed/NCBI
|
|
56
|
Mahdi Y, Khmou M, Souadka A, Agouri H El,
Ech-charif S, Mounjid C and Khannoussi B El: Correlation between
KRAS and NRAS mutational status and clinicopathological features in
414 cases of metastatic colorectal cancer in Morocco: The largest
North African case series. BMC Gastroenterol. 23:1932023.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Irahara N, Baba Y, Nosho K, Shima K, Yan
L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM and Ogino S:
NRAS mutations are rare in colorectal cancer. Diagnostic Mol
Pathol. 19:157–163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang YY, Lin PC, Lin HH, Lin JK, Chen WS,
Jiang JK, Yang SH, Liang WY and Chang SC: Mutation spectra of RAS
gene family in colorectal cancer. Am J Surg. 212:537–544.e3. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shen Y, Wang J, Han X, Yang H, Wang S, Lin
D and Shi Y: Effectors of epidermal growth factor receptor pathway:
The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in
colorectal cancer characteristics and personalized medicine. PLoS
One. 8:e816282013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jouini R, Ferchichi M, BenBrahim E, Ayari
I, Khanchel F, Koubaa W, Saidi O, Allani R and Chadli-Debbiche A:
KRAS and NRAS pyrosequencing screening in Tunisian colorectal
cancer patients in 2015. Heliyon. 5:e013302019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tran B, Kopetz S, Tie J, Gibbs P, Jiang
ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O and Desai J: Impact of
BRAF mutation and microsatellite instability on the pattern of
metastatic spread and prognosis in metastatic colorectal cancer.
Cancer. 117:4623–4632. 2011. View Article : Google Scholar : PubMed/NCBI
|
